Prorenin and the (pro)renin receptor: Do they have a pathogenic role in the retina?

Frontiers in Bioscience - Elite

Volumn 2 E, Issue 3, 2010, Pages 1054-1064

  Wilkinson Berka, Jennifer L ^a   Miller, Antonia G ^a   Fletcher, Erica L ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiogenesis; Inflammation; Prorenin; Prorenin receptor; Retinopathy; Review

Indexed keywords

ANGIOTENSIN II; CELL SURFACE RECEPTOR; PRORENIN RECEPTOR; RENIN;

DIABETIC RETINOPATHY; HUMAN; METABOLISM; NEWBORN; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; RETINA MACULA DEGENERATION; RETROLENTAL FIBROPLASIA; REVIEW;

ANGIOTENSIN II; DIABETIC RETINOPATHY; HUMANS; INFANT, NEWBORN; MACULAR DEGENERATION; RECEPTORS, CELL SURFACE; RENIN; RETINA; RETINOPATHY OF PREMATURITY;

EID: 77957371849     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e163     Document Type: Article

References (93)

1. J. A. Luetscher, F. B. Kraemer, D. M. Wilson, H. C. Schwartz and M. Bryer-Ash: Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med, 312(22), 1412-7 (1985) (Pubitemid 15083658)
2. A. A. Franken, F. H. Derkx, M. A. Schalekamp, A. J. Man in t'Veld, W. C. Hop, E. H. van Rens and P. T. de Jong: Association of high plasma prorenin with diabetic retinopathy. J Hypertens Suppl, 6(4), S461-3 (1988)
3. A. H. Danser, M. A. van den Dorpel, J. Deinum, F. H. Derkx, A. A. Franken, E. Peperkamp, P. T. de Jong and M. A. Schalekamp: Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab, 68(1), 160-7 (1989) (Pubitemid 19028740)
4. G. Nguyen, F. Delarue, C. Burckle, L. Bouzhir, T. Giller and J. D. Sraer: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest, 109(11), 1417-27 (2002) (Pubitemid 34596167)
5. F. Suzuki, M. Hayakawa, T. Nakagawa, U. M. Nasir, A. Ebihara, A. Iwasawa, Y. Ishida, Y. Nakamura and K. Murakami: Human prorenin has "gate and handle" regions for its non-proteolytic activation. J Biol Chem, 278(25), 22217-22 (2003) (Pubitemid 36830267)
6. S. Satofuka, A. Ichihara, N. Nagai, T. Koto, H. Shinoda, K. Noda, Y. Ozawa, M. Inoue, K. Tsubota, H. Itoh, Y. Oike and S. Ishida: Role of nonproteolytically activated prorenin in pathologic, but not physiologic, retinal neovascularization. Invest Ophthalmol Vis Sci, 48(1), 422-9 (2007) (Pubitemid 47251433)
7. S. Satofuka, A. Ichihara, N. Nagai, K. Noda, Y. Ozawa, A. Fukamizu, K. Tsubota, H. Itoh, Y. Oike and S. Ishida: (Pro) renin receptor promotes choroidal neovascularization by activating its signal transduction and tissue renin-angiotensin system. Am J Pathol, 173 (6),
8. S. Satofuka, A. Ichihara, N. Nagai, K. Noda, Y. Ozawa, A. Fukamizu, K. Tsubota, H. Itoh, Y. Oike and S. Ishida: (Pro) renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes, 58 (7),
9. S. Satofuka, A. Ichihara, N. Nagai, K. Yamashiro, T. Koto, H. Shinoda, K. Noda, Y. Ozawa, M. Inoue, K. Tsubota, F. Suzuki, Y. Oike and S. Ishida: Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin. Invest Ophthalmol Vis Sci, 47(6), 2686-92 (2006)
10. A. Ichihara, Y. Kaneshiro, T. Takemitsu, M. Sakoda, F. Suzuki, T. Nakagawa, A. Nishiyama, T. Inagami and M. Hayashi: Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension, 47(5), 894-900 (2006) (Pubitemid 44297561)
11. A. Ichihara, F. Suzuki, T. Nakagawa, Y. Kaneshiro, T. Takemitsu, M. Sakoda, A. H. Nabi, A. Nishiyama, T. Sugaya, M. Hayashi and T. Inagami: Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol, 17(7), 1950-61 (2006) (Pubitemid 44036179)
12. J. L. Wilkinson-Berka: Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol, 38(5-6), 752-65 (2006) (Pubitemid 43372053)
13. J. L. Berka, A. J. Stubbs, D. Z. Wang, R. DiNicolantonio, D. Alcorn, D. J. Campbell and S. L. Skinner: Renin-containing Muller cells of the retina display endocrine features. Invest Ophthalmol Vis Sci, 36(7), 1450-8 (1995)
14. N. Nagai, Y. Oike, K. Izumi-Nagai, T. Urano, Y. Kubota, K. Noda, Y. Ozawa, M. Inoue, K. Tsubota, T. Suda and S. Ishida: Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization. Arterioscler Thromb Vasc Biol, 26(10), 2252-9 (2006) (Pubitemid 44465719)
15. P. Senanayake, J. Drazba, K. Shadrach, A. Milsted, E. Rungger-Brandle, K. Nishiyama, S. Miura, S. Karnik, J. E. Sears and J. G. Hollyfield: Angiotensin II and its receptor subtypes in the human retina. Invest Ophthalmol Vis Sci, 48(7), 3301-11 (2007) (Pubitemid 351261177)
16. T. H. Wheeler-Schilling, K. Kohler, M. Sautter and E. Guenther: Angiotensin II receptor subtype gene expression and cellular localization in the retina and non-neuronal ocular tissues of the rat. Eur J Neurosci, 11(10), 3387-94 (1999) (Pubitemid 29484235)
17. S. Sarlos and J. L. Wilkinson-Berka: The renin-angiotensin system and the developing retinal vasculature. Invest Ophthalmol Vis Sci, 46(3), 1069-77 (2005) (Pubitemid 41321047)
18. C. Tikellis, C. I. Johnston, J. M. Forbes, W. C. Burns, M. C. Thomas, R. A. Lew, M. Yarski, A. I. Smith and M. E. Cooper: Identification of angiotensin converting enzyme 2 in the rodent retina. Curr Eye Res, 29(6), 419-27 (2004) (Pubitemid 40138381)
19. L. E. Downie, K. Vessey, A. Miller, M. M. Ward, M. J. Pianta, A. J. Vingrys, J. L. Wilkinson-Berka and E. L. Fletcher: Neuronal and glial cell expression of angiotensin II type 1 (AT1) and type 2 (AT2) receptors in the rat retina. Neuroscience, 161(1), 195-213 (2009)
20. J. L. Wilkinson-Berka, G. Tan, K. Jaworski and A. G. Miller: Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res, 104(1), 124-33 (2009)
21. A. Contrepas, J. Walker, A. Koulakoff, K. J. Franek, F. Qadri, C. Giaume, P. Corvol, C. E. Schwartz and G. Nguyen: A role of the (pro) renin receptor in neuronal cell differentiation. Am J Physiol Regul Integr Comp Physiol, 297(2), R250-7 (2009)
22. O. Alcazar, S. W. Cousins, G. E. Striker and M. E. Marin-Castano: (Pro) renin receptor is expressed in human retinal pigment epithelium and participates in extracellular matrix remodeling. Exp Eye Res (2009)
23. J. Wagner, A. H. Jan Danser, F. H. Derkx, T. V. de Jong, M. Paul, J. J. Mullins, M. A. Schalekamp and D. Ganten: Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol, 80(2), 159-63 (1996) (Pubitemid 26058551)
24. R. E. Gilbert, H. Krum, J. Wilkinson-Berka and D. J. Kelly: The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabet Med, 20(8), 607-21 (2003) (Pubitemid 36966554)
25. H. Yokota, T. Nagaoka, F. Mori, T. Hikichi, H. Hosokawa, H. Tanaka, Y. Ishida, F. Suzuki and A. Yoshida: Prorenin levels in retinopathy of prematurity. Am J Ophthalmol, 143(3), 531-3 (2007)
26. E. Ishizaki, S. Takai, M. Ueki, T. Maeno, M. Maruichi, T. Sugiyama, H. Oku, T. Ikeda and M. Miyazaki: Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am J Ophthalmol, 141(1), 129-134 (2006)
27. C. J. Moravski, D. J. Kelly, M. E. Cooper, R. E. Gilbert, J. F. Bertram, S. Shahinfar, S. L. Skinner and J. L. Wilkinson-Berka: Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension, 36(6), 1099-104 (2000)
28. C. J. Moravski, S. L. Skinner, A. J. Stubbs, S. Sarlos, D. J. Kelly, M. E. Cooper, R. E. Gilbert and J. L. Wilkinson-Berka: The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am J Pathol, 162(1), 151-60 (2003) (Pubitemid 36041997)
29. J. A. Nadal, G. M. Scicli, L. A. Carbini and A. G. Scicli: Angiotensin II stimulates migration of retinal microvascular pericytes: involvement of TGF-beta and PDGF-BB. Am J Physiol Heart Circ Physiol, 282(2), H739-48 (2002) (Pubitemid 34655001)
30. S. Yamagishi, S. Amano, Y. Inagaki, T. Okamoto, H. Inoue, M. Takeuchi, H. Choei, N. Sasaki and S. Kikuchi: Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation. Drugs Exp Clin Res, 29(2), 75-80 (2003) (Pubitemid 36975512)
31. S. Yamagishi, M. Takeuchi, T. Matsui, K. Nakamura, T. Imaizumi and H. Inoue: Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. FEBS Lett, 579(20), 4265-70 (2005) (Pubitemid 41116350)
32. A. Otani, H. Takagi, H. Oh, S. Koyama and Y. Honda: Angiotensin II induces expression of the Tie2 receptor ligand, angiopoietin-2, in bovine retinal endothelial cells. Diabetes, 50(4), 867-75 (2001) (Pubitemid 32242646)
33. A. Otani, H. Takagi, K. Suzuma and Y. Honda: Angiotensin II potentiates vascular endothelial growth factorinduced angiogenic activity in retinal microcapillary endothelial cells. Circ Res, 82(5), 619-28 (1998) (Pubitemid 28129033)
34. A. Otani, H. Takagi, H. Oh, K. Suzuma, M. Matsumura, E. Ikeda and Y. Honda: Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. Invest Ophthalmol Vis Sci, 41(5), 1192-9 (2000) (Pubitemid 30187560)
35. P. Chen, A. M. Guo, P. A. Edwards, G. Trick and A. G. Scicli: Role of NADPH oxidase and ANG II in diabetesinduced retinal leukostasis. Am J Physiol Regul Integr Comp Physiol, 293(4), R1619-29 (2007)
36. D. L. Gibson, S. B. Sheps, S. H. Uh, M. T. Schechter and A. Q. McCormick: Retinopathy of prematurity-induced blindness: birth weight-specific survival and the new epidemic. Pediatrics, 86(3), 405-12 (1990) (Pubitemid 20334974)
37. K. Liu, J. D. Akula, C. Falk, R. M. Hansen and A. B. Fulton: The retinal vasculature and function of the neural retina in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci, 47(6), 2639-47 (2006) (Pubitemid 351639852)
38. S. Mohamed, K. Schaa, M. E. Cooper, E. Ahrens, A. Alvarado, T. Colaizy, M. L. Marazita, J. C. Murray and J. M. Dagle: Genetic contributions to the development of retinopathy of prematurity. Pediatr Res, 65(2), 193-7 (2009)
39. M. Lonchampt, L. Pennel and J. Duhault: Hyperoxia/normoxia-driven retinal angiogenesis in mice: a role for angiotensin II. Invest Ophthalmol Vis Sci, 42(2), 429-32 (2001) (Pubitemid 32121475)
40. M. Tadesse, Y. Yan, P. Yossuck and R. D. Higgins: Captopril improves retinal neovascularization via endothelin-1. Invest Ophthalmol Vis Sci, 42(8), 1867-72 (2001) (Pubitemid 32652366)
41. H. Nakamura, M. Yamazaki, T. Ohyama, T. Inoue, N. Arakawa, Y. Domon and T. Yokoyama: Role of angiotensin II type 1 receptor on retinal vascular leakage in a rat oxygeninduced retinopathy model. Ophthalmic Res, 41(4), 210-5 (2009)
42. S. Sarlos, B. Rizkalla, C. J. Moravski, Z. Cao, M. E. Cooper and J. L. Wilkinson-Berka: Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol, 163(3), 879-87 (2003) (Pubitemid 37040124)
43. J. Stone, A. Itin, T. Alon, J. Pe'er, H. Gnessin, T. Chan-Ling and E. Keshet: Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci, 15(7 Pt 1), 4738-47 (1995)
44. J. Stone, T. Chan-Ling, J. Pe'er, A. Itin, H. Gnessin and E. Keshet: Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci, 37(2), 290-9 (1996) (Pubitemid 26057055)
45. L. E. Downie, M. J. Pianta, A. J. Vingrys, J. L. Wilkinson-Berka and E. L. Fletcher: AT1 receptor inhibition prevents astrocyte degeneration and restores vascular growth in oxygeninduced retinopathy. Glia, 56(10), 1076-90 (2008)
46. R. E. Gilbert, D. J. Kelly, A. J. Cox, J. L. Wilkinson-Berka, J. R. Rumble, T. Osicka, S. Panagiotopoulos, V. Lee, E. C. Hendrich, G. Jerums and M. E. Cooper: Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia, 43(11), 1360-7 (2000)
47. J. Z. Zhang, X. Xi, L. Gao and T. S. Kern: Captopril inhibits capillary degeneration in the early stages of diabetic retinopathy. Curr Eye Res, 32(10), 883-9 (2007) (Pubitemid 350034786)
48. J. L. Wilkinson-Berka, G. Tan, K. Jaworski and S. Ninkovic: Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina. Am J Hypertens, 20(4), 423-30 (2007) (Pubitemid 46441750)
49. A. M. Joussen, T. Murata, A. Tsujikawa, B. Kirchhof, S. E. Bursell and A. P. Adamis: Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol, 158(1), 147-52 (2001) (Pubitemid 32096479)
50. P. Chen, G. M. Scicli, M. Guo, J. D. Fenstermacher, D. Dahl, P. A. Edwards and A. G. Scicli: Role of angiotensin II in retinal leukostasis in the diabetic rat. Exp Eye Res, 83(5), 1041-51 (2006) (Pubitemid 44397025)
51. F. Mori, T. Hikichi, T. Nagaoka, J. Takahashi, N. Kitaya and A. Yoshida: Inhibitory effect of losartan, an AT1 angiotensin II receptor antagonist, on increased leucocyte entrapment in retinal microcirculation of diabetic rats. Br J Ophthalmol, 86(10), 1172-4 (2002)
52. K. C. Silva, C. C. Pinto, S. K. Biswas, D. S. Souza, J. B. de Faria and J. M. de Faria: Prevention of hypertension abrogates early inflammatory events in the retina of diabetic hypertensive rats. Exp Eye Res, 85(1), 123-9 (2007) (Pubitemid 47017272)
53. E. Rungger-Brandle, A. A. Dosso and P. M. Leuenberger: Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci, 41(7), 1971-80 (2000) (Pubitemid 30354375)
54. J. K. Krady, A. Basu, C. M. Allen, Y. Xu, K. F. LaNoue, T. W. Gardner and S. W. Levison: Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes, 54(5), 1559-65 (2005) (Pubitemid 40586690)
55. M. J. Gastinger, R. S. Singh and A. J. Barber: Loss of cholinergic and dopaminergic amacrine cells in streptozotocindiabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci, 47(7), 3143-50 (2006) (Pubitemid 351639794)
56. A. J. Barber, E. Lieth, S. A. Khin, D. A. Antonetti, A. G. Buchanan and T. W. Gardner: Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest, 102(4), 783-91 (1998) (Pubitemid 28399611)
57. E. Lieth, A. J. Barber, B. Xu, C. Dice, M. J. Ratz, D. Tanase and J. M. Strother: Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes, 47(5), 815-20 (1998) (Pubitemid 28201813)
58. S. H. Park, J. W. Park, S. J. Park, K. Y. Kim, J. W. Chung, M. H. Chun and S. J. Oh: Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina. Diabetologia, 46(9), 1260-8 (2003)
59. J. A. Phipps, E. L. Fletcher and A. J. Vingrys: Paired-flash identification of rod and cone dysfunction in the diabetic rat. Invest Ophthalmol Vis Sci, 45(12), 4592-600 (2004) (Pubitemid 39564688)
60. B. V. Bui, J. A. Armitage, M. Tolcos, M. E. Cooper and A. J. Vingrys: ACE inhibition salvages the visual loss caused by diabetes. Diabetologia, 46(3), 401-8 (2003) (Pubitemid 36547596)
61. D. R. Matthews, I. M. Stratton, S. J. Aldington, R. R. Holman and E. M. Kohner: Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol, 122(11), 1631-40 (2004) (Pubitemid 39473407)
62. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ, 317(7160), 713-20 (1998)
63. R. Malhotra, J. Sadoshima, F. C. Brosius, 3rd and S. Izumo: Mechanical stretch and angiotensin II differentially upregulate the renin-angiotensin system in cardiac myocytes In vitro. Circ Res, 85(2), 137-46 (1999) (Pubitemid 29343312)
64. I. Suzuma, Y. Hata, A. Clermont, F. Pokras, S. L. Rook, K. Suzuma, E. P. Feener and L. P. Aiello: Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension. Diabetes, 50(2), 444-54 (2001) (Pubitemid 32140442)
65. K. C. Silva, M. A. Rosales, S. K. Biswas, J. B. Lopes de Faria and J. M. Lopes de Faria: Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes, 58(6), 1382-90 (2009)
66. J. A. Phipps, J. L. Wilkinson-Berka and E. L. Fletcher: Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol. Invest Ophthalmol Vis Sci, 48(2), 927-34 (2007) (Pubitemid 351260731)
67. Z. Zheng, H. Chen, X. Xu, C. Li and Q. Gu: Effects of angiotensin-converting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy. Exp Eye Res, 84(4), 745-52 (2007) (Pubitemid 46400640)
68. J. Ramser, F. E. Abidi, C. A. Burckle, C. Lenski, H. Toriello, G. Wen, H. A. Lubs, S. Engert, R. E. Stevenson, A. Meindl, C. E. Schwartz and G. Nguyen: A unique exonic splice enhancer mutation in a family with X-linked mental retardation and epilepsy points to a novel role of the renin receptor. Hum Mol Genet, 14(8), 1019-27 (2005) (Pubitemid 40575877)
69. R. O. Estacio, B. W. Jeffers, N. Gifford and R. W. Schrier: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care, 23 Suppl 2, B54-64 (2000) (Pubitemid 30185779)
70. A. Patel, S. MacMahon, J. Chalmers, B. Neal, M. Woodward, L. Billot, S. Harrap, N. Poulter, M. Marre, M. Cooper, P. Glasziou, D. E. Grobbee, P. Hamet, S. Heller, L. S. Liu, G. Mancia, C. E. Mogensen, C. Y. Pan, A. Rodgers and B. Williams: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet, 370(9590), 829-40 (2007) (Pubitemid 47362321)
71. N. Chaturvedi, A. K. Sjolie, J. M. Stephenson, H. Abrahamian, M. Keipes, A. Castellarin, Z. Rogulja-Pepeonik and J. H. Fuller: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet, 351(9095), 28-31 (1998)
72. N. Chaturvedi, M. Porta, R. Klein, T. Orchard, J. Fuller, H. H. Parving, R. Bilous and A. K. Sjolie: Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet, 372(9647), 1394-402 (2008)
73. A. K. Sjolie, R. Klein, M. Porta, T. Orchard, J. Fuller, H. H. Parving, R. Bilous and N. Chaturvedi: Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet, 372(9647), 1385-93 (2008)
74. M. Mauer, B. Zinman, R. Gardiner, S. Suissa, A. Sinaiko, T. Strand, K. Drummond, S. Donnelly, P. Goodyer, M. C. Gubler and R. Klein: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med, 361(1), 40-51 (2009)
75. W. R. Green: Histopathology of age-related macular degeneration. Mol Vis, 5, 27 (1999)
76. S. L. Fine, J. W. Berger, M. G. Maguire and A. C. Ho: Age-related macular degeneration. N Engl J Med, 342(7), 483-92 (2000) (Pubitemid 30100237)
77. R. Klein, B. E. Klein, S. C. Tomany and K. J. Cruickshanks: The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. Ophthalmology, 110(4), 636-43 (2003) (Pubitemid 36520056)
78. L. Hyman, A. P. Schachat, Q. He and M. C. Leske: Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol, 118(3), 351-8 (2000)
79. T. Hikichi, F. Mori, A. Takamiya, M. Sasaki, Y. Horikawa, M. Takeda and A. Yoshida: Inhibitory effect of losartan on laser-induced choroidal neovascularization in rats. Am J Ophthalmol, 132(4), 587-9 (2001) (Pubitemid 32904592)
80. N. Nagai, Y. Oike, K. Izumi-Nagai, T. Koto, S. Satofuka, H. Shinoda, K. Noda, Y. Ozawa, M. Inoue, K. Tsubota and S. Ishida: Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin. Invest Ophthalmol Vis
81. W. W. Batenburg, M. Krop, I. M. Garrelds, R. de Vries, R. J. de Bruin, C. A. Burckle, D. N. Muller, M. Bader, G. Nguyen and A. H. Danser: Prorenin is the endogenous agonist of the (pro) renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro) renin receptor. J Hypertens, 25(12), 2441-53 (2007) (Pubitemid 350060383)
82. Y. Huang, N. A. Noble, J. Zhang, C. Xu and W. A. Border: Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int, 72(1), 45-52 (2007) (Pubitemid 47014443)
83. J. J. Saris, P. A. t Hoen, I. M. Garrelds, D. H. Dekkers, J. T. den Dunnen, J. M. Lamers and A. H. Jan Danser: Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension, 48(4), 564-71 (2006) (Pubitemid 44843857)
84. G. Nguyen, F. Delarue, J. Berrou, E. Rondeau and J. D. Sraer: Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int, 50(6), 1897-903 (1996) (Pubitemid 26417532)
85. A. Ichihara, M. Hayashi, Y. Kaneshiro, F. Suzuki, T. Nakagawa, Y. Tada, Y. Koura, A. Nishiyama, H. Okada, M. N. Uddin, A. H. Nabi, Y. Ishida, T. Inagami and T. Saruta: Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest, 114(8), 1128-35 (2004) (Pubitemid 39578702)
86. Y. Kaneshiro, A. Ichihara, M. Sakoda, T. Takemitsu, A. H. Nabi, M. N. Uddin, T. Nakagawa, A. Nishiyama, F. Suzuki, T. Inagami and H. Itoh: Slowly progressive, angiotensin IIindependent glomerulosclerosis in human (pro) renin receptortransgenic rats. J Am Soc Nephrol, 18(6), 1789-95 (2007) (Pubitemid 46870315)
87. S. Feldt, U. Maschke, R. Dechend, F. C. Luft and D. N. Muller: The putative (pro) renin receptor blocker HRP fails to prevent (pro) renin signaling. J Am Soc Nephrol, 19(4), 743-8 (2008)
88. D. N. Muller, B. Klanke, S. Feldt, N. Cordasic, A. Hartner, R. E. Schmieder, F. C. Luft and K. F. Hilgers: (Pro) renin receptor peptide inhibitor "handle-region" peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension, 51(3), 676-81 (2008) (Pubitemid 351301520)
89. Z. Shan, A. E. Cuadra, C. Sumners and M. K. Raizada: Characterization of a functional (pro) renin receptor in rat brain neurons. Exp Physiol, 93(5), 701-8 (2008) (Pubitemid 351595061)
90. A. Amsterdam, R. M. Nissen, Z. Sun, E. C. Swindell, S. Farrington and N. Hopkins: Identification of 315 genes essential for early zebrafish development. Proc Natl Acad Sci U S A, 101(35), 12792-7 (2004) (Pubitemid 39167537)
91. M. van den Heuvel, W. W. Batenburg and A. H. Danser: Diabetic complications: a role for the prorenin-(pro) renin receptor-TGF-beta1 axis? Mol Cell Endocrinol, 302(2), 213-8 (2009)
92. J. L. Wilkinson-Berka and D. J. Campbell: (Pro) renin receptor: a treatment target for diabetic retinopathy? Diabetes, 58(7), 1485-7 (2009)
93. K. Kohler, T. Wheeler-Schilling, B. Jurklies, E. Guenther and E. Zrenner: Angiotensin II in the rabbit retina. Vis Neurosci, 14(1), 63-71 (1997) (Pubitemid 27415946)